Selective factor Xa inhibition with fondaparinux: From concept to clinical benefit

European Heart Journal, Supplement

Volumn 10, Issue SUPPL. C, 2008, Pages

  Turpie, Alexander G G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Acute coronary syndromes; Anticoagulant; Factor Xa; Fondaparinux; Heparin; Venous thrombo embolism

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 77949595832     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sun003     Document Type: Review

References (44)

1. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(Suppl.1):60-64.
2. Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, Zandberg P, van Amsterdam RGM, van Boeckel CAA, Meuleman DG. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15:1-26.
3. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-144.
4. Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41(Suppl.2):1-9. (Pubitemid 35155551)
5. Lieu C, Shi J, Donat F, Van Horn R, Brian W, Newton J, Delbressine L, Vos R. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002;41(Suppl.2):19-26.
6. Faaij RA, Burggraaf J, Schoemaker RC, de Greef R, Cohen AF. Absence of interaction between the synthetic pentasaccharide fondaparinux sodium and oral warfarin. Clin Pharmacokinet 2002;41(Suppl.2): 27-29. (Pubitemid 35155554)
7. Ollier C, Santoni A, Faaij RA, Duvauchelle T, van Haard PM, Schoemaker RC, Cohen AF, de Greef R, Burggraaf J. Interaction of fondaparinux sodium with acetylsalicylic acid and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002;41(Suppl.2): 31-37. (Pubitemid 35155555)
8. Mant T, Fournié P, Ollier C, Donat F, Necciari J. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002;41(Suppl. 2):39-45. (Pubitemid 35155556)
9. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119(Suppl. 1):132S-175S.
10. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products for prophylaxis of intraand postoperative venous thromboembolic risk. The European Agency for the Evaluation of Medicinal Products. London, 29 June 2000; CPMP/EWP/707/98.
11. Segers AE, Prins MH, Lensing AW, Buller HR. Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies? J Thromb Haemost 2005;3:1099-1102.
12. Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-625.
13. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359: 1715-1720.
14. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726.
15. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
16. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298-1304.
17. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylactic Studies. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized studies. Arch Intern Med 2002;162:1833-1840.
18. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003;90:364-366.
19. Food and Drug Administration (USA). Prescribing Information on fondaparinux, http://www.fda.gov/medwatch/SAFETY/2005/MAY-PI/Arixtra-PI.pdf
20. Eriksson BI, Lassen MR, on behalf of the PENTHIFRA-PLUS investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163:1337-1342.
21. Turpie AGG, Bauer KA, Caprini JA, Comp PP, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression versus intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, doubleblind comparison. J Thromb Haemost 2007;5:1854-1861.
22. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212-1220.
23. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-329.
24. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341:793-800.
25. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-879.
26. Eikelboom J, Cohen AT, Turpie AGG. Fondaparinux reduces symptomatic pulmonary embolism and death in patients hospitalized with congestive heart failure: a sub-analysis of the randomized ARTEMIS trial. (Abstract P477). Eur Heart J 2007;28(Suppl.1):50.
27. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-873.
28. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349: 1695-1702.
29. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation 2000;102:2726-2731.
30. Davidson BL, Buller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW, Matisse Investigators. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the MATISSE trials. J Thromb Haemost 2007;5:1191-1194.
31. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van de Werf F, PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/ SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-1724.
32. Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U, PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes; The Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol 2004;43:2183-2190.
33. Mehta SR, Steg PG, Granger CB, Bassand J-P, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJG, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KAA, Yusuf S, for the ASPIRE Investigators. Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005;111:1390-1397.
34. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
35. Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S, OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007;147:304-310.
36. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KAA, Yusuf S. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50:1742-1751.
37. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-1530.
38. Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf 2005;4: 707-721.
39. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-2655.
40. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006;40:1383-1387.
41. European Agency for the Evaluation of Medicinal Products. Summary of Product Characteristics of fondaparinux; ESC Committee of Practice Guideliness (CPG), http://www.emea.europa.eu/humandocs/PDFs/EPAR/arixtra/H-403-PI-en.pdf
42. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl.3):338S-400S.
43. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W; ESC Committee of Practice Guideliness (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Kristensen SD, Widimsky P, McGregor K, Sechtem U, Tendera M, Hellemans I, Gomez JL, Silber S, Funck-Brentano C, Kristensen SD, Andreotti F, Benzer W, Bertrand M, Betriu A, De Caterina R, De Sutter J, Falk V, Ortiz AF, Gitt A, Hasin Y, Huber K, Kornowski R, Lopez-Sendon J, Morais J, Nordrehaug JE, Silber S, Steg PG, Thygesen K, Tubaro M, Turpie AG, Verheugt F, Windecker S. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-1660.
44. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.